How many investments has aMoon made?

aMoon has 44 tracked investments, 1 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.

What stage does aMoon invest at?

aMoon invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.

Where is aMoon located?

aMoon is headquartered in Ra'anana, IL.

Who does aMoon co-invest with?

aMoon most often shares deals with F-Prime Capital, Khosla Ventures, Lightspeed Venture Partners, among 76 tracked co-investors.

aMoon

Venture capital

Ra'anana · Seed–Late Stage · 19 people tracked

Also known as aMoon Velocity Limited Partnership · AMOON VENTURES Y.SH. LTD.

★ Follow + Add to CRM ⤳ Find an introduction

✨ Fox Verdict

Investment thesis

aMoon backs exceptional entrepreneurs harnessing groundbreaking science and technology to transform healthcare. Through aMoon Velocity (early-stage) and aMoon Growth (late-stage), the firm targets disruptive solutions for high unmet medical needs across biopharma, medtech and health technology. Beyond capital, aMoon provides hands-on support via its Alpha team, a global talent engine, a Bridges program connecting portfolio companies with co-investors, research institutions, payers, providers and major corporations, and proprietary research and intelligence. Its team of scientists, physicians, entrepreneurs and investors aims to make healthcare more affordable, higher quality and more accessible.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Global

Source: firm website, verified Aug 25, 2026.

Stage

Seed–Late Stage

Ra'anana, NY, IL

Instruments

Equity

Founded

2016

Last 12 months

4 investments

AUM

$1.3B

VC funds

Tracked investments

Team · 19 people

from the firm's website & public directories

Moshic Mor· General Partner· Israelin

Moshic Mor is a General Partner at aMoon, where he co-leads Velocity, its early-stage fund for healthcare technology. He co-founded SPL WorldGroup in 1993 and served as CEO until 2000, growing it to 1,000 employees before its 2003 acquisition by Oracle, then spent 19 years at Greylock Partners, co-founding Greylock Israel (now 83North) in 2006 and serving as a venture partner from 2012 to 2019. He holds a BS in Economics from Tel Aviv University and an MBA from Harvard Business School.

Reut Shema· Managing Director· Boston, Massachusettsin 𝕏

Reut Shema is a Partner at aMoon and a scientist by training who sources and leads investments in science-driven companies. She joined aMoon in May 2018 and helps lead aMoon Edge, the firm's public equity fund. Before aMoon, she was a VP of Business Development and scientific advisor at Greenfield Partners, and she previously conducted research at Harvard, MIT's Broad Institute, and the Weizmann Institute, where she completed her PhD; she holds a BSc in Biology and Psychology from Tel Aviv University.

r•••@amoon.fundreveal

Roy Wiesner· Partner, aMoon Velocity· Israelin

Roy Wiesner is a Partner at aMoon Velocity, where he leads deal teams and sourcing and heads StarFinder Lab, aMoon's collaboration with Roche Diagnostics. He has nearly 20 years of investment experience, working first as an M&A and private equity lawyer in New York, Hong Kong, and Tel Aviv, and later as a venture capitalist, including as CEO of Hutchison Kinrot, an incubator and seed investor in water technologies and cleantech owned by CK Hutchison Holdings. He holds an LLB from the Hebrew University of Jerusalem and a dual MPA from the London School of Economics and Columbia University, and is a certified lawyer in Israel and New York.

r•••@amoon.fundreveal

Todd Sone· General Partner· Israelin

Todd Sone is a General Partner at aMoon who co-leads the firm's Growth team and has more than 25 years of healthcare investment experience across sell-side, LP, and buy-side roles. He was previously a Managing Director at Signet Healthcare Partners and an Investment Director at the family office Joddes, and earlier worked as an equity analyst covering US pharmaceuticals at Morgan Stanley and Goldman Sachs and as a consultant at Mercer Management Consulting. He holds a B.Com from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.

t•••@amoon.fundreveal

Tomer Berkovitz· General Partner· Tel Aviv, Israelin

Tomer Berkovitz is a Managing Partner at aMoon, which he joined in February 2018, focusing on investments at the intersection of healthcare and technology. He previously worked as an investment banker at J.P. Morgan in New York, where he led healthcare within the Corporate Finance Advisory team, and later served as CFO and COO of Alcobra, a NASDAQ-listed biopharmaceutical company. He holds a Ph.D. in Finance from Columbia Business School, as well as a B.A. in Economics and Management and an M.Sc. in Finance and Accounting from Tel Aviv University.

t•••@amoon.fundreveal

Yair Schindel· Managing Partner· Boston, Massachusettsin 𝕏

Yair Schindel is Co-Founder and Managing Partner of aMoon, which he co-founded in 2017. A physician by training, he previously served as founding CEO of Digital Israel within the Prime Minister's Office and as CEO of Startup Nation Central. He earned his BSc and MD from Ben-Gurion University's Goldman Medical School and an MBA from Harvard Business School, and served for five years as a physician with IDF Special Forces.

y•••@amoon.fundreveal

Yaron Daniely· General Partner· Israelin

Yaron Daniely is a General Partner at aMoon, where he co-leads Velocity, an early-stage fund focused on cutting-edge technologies aimed at accelerating cures. Before aMoon, he was President and CEO of Yissum, Hebrew University's technology transfer company, and Co-Chairperson of the Israel Technology Transfer Network, following 14 years as a senior executive (10 as CEO) at private and NASDAQ-traded biopharma and biotech companies. He holds a PhD from the Sackler Institute of Graduate Biomedical Sciences at NYU School of Medicine and an MBA from the Technion.

Adam Kotzen· Principal, aMoon Growth· Tel Aviv-Yafo, Tel Aviv District, Israelin

Adam Kotzen is a Principal at aMoon Growth, where he focuses on identifying and evaluating late-stage investment opportunities using his background in finance and strategic analysis. He previously worked as an investment banker at Credit Suisse on M&A in African markets, including advising Anglo American Platinum on the disposal of certain South African mining assets, and later worked in Corporate Development at ADAMA Agricultural Solutions. He holds a Business Science degree in Finance and Economics from the University of Cape Town.

a•••@amoon.fundreveal

Tamir Maixner· Principal, aMoon Growth· Greater Bostonin

Tamir Maixner is a Principal at aMoon Growth, where he focuses on late-stage HealthTech investments and works with portfolio management teams on value creation. He has been with aMoon since its founding. Before entering venture capital, he served six years as an officer in the Israeli Navy's Shayetet 13 unit. He holds an MBA from Stanford Graduate School of Business and an MA in Finance and an LLB in Law from Reichman University in Israel.

t•••@amoon.fundreveal

Tamar Farfel-Becker· Principal· Israel

Isaac Devash· Venture Partner· Israel

Daniel Sass· Associate· Israelin

Daniel Sass is a South African-trained physician who earned his medical degree from the University of the Witwatersrand and trained in Emergency Medicine through the Colleges of Medicine of South Africa, practicing in emergency departments in Cape Town. He moved to Israel in 2021 to pursue an MBA in Technology, Entrepreneurship, and Innovation at Tel Aviv University, and previously served as Director of Sales and Business Development at Pheno.AI. At aMoon he evaluates late-stage investment opportunities for the firm's Growth Fund.

David Esra· Analyst, aMoon Velocity· Tel Aviv District, Israelin

David Esra is an Analyst at aMoon Velocity, where he evaluates early-stage investment opportunities and contributes to the firm's internal value-creation team, Alpha, which supports portfolio companies. Trained as a medical doctor, he earned his MD from the University of the Witwatersrand in Johannesburg and worked for two years in public hospitals around Cape Town, including Groote Schuur Hospital. He applies this clinical background to his work in life sciences investing.

Hagai Marmor-Kollet· Associate· Greater Bostonin

Hagai Marmor-Kollet is an Associate at aMoon Growth, where he sources and evaluates late-stage investment opportunities in life science tools and diagnostics. He previously served as Platform Team Lead at 1E Therapeutics working on oligonucleotide-based therapies, and contributed to cancer diagnostic test development at Rosetta Genomics. He holds an MSc and PhD from the Weizmann Institute of Science and was later a staff scientist at Massachusetts General Hospital and Harvard Medical School, leading translational research in neurodegeneration and pain.

Osnat Tirosh· Chief People Officer and Chief of Staff· Ra'anana, Israelin

Osnat Tirosh is Chief People Officer and Chief of Staff at aMoon, where she leads people strategy and organizational planning. She has over two decades of human capital leadership experience with high-growth global technology companies, previously serving as Chief People and Corporate Development Officer at Cellebrite and in leadership roles at Better Place, Passave, PMC-Sierra, NLayers, and Pixel. She is a certified life and business coach and holds an MSc in Management Engineering from the University of Bridgeport.

Patrick Rivers· Portfolio Manager, aMoon Edge· Chicago, Illinois, United Statesin

Patrick Rivers is a Portfolio Manager for aMoon Edge, overseeing the fund's public healthcare investments and leading private therapeutics investments for aMoon Growth. Before joining aMoon in August 2024, he was Managing Director and Head of Research at Aquilo Capital Management, a biotechnology-focused investment fund concentrating on small- and mid-cap public therapeutics companies. He earlier worked as a bench scientist in drug development at Xoma, Exelixis, and Sutro Biopharma, and holds an MBA from UC Berkeley's Haas School of Business and a BS in Chemical Engineering from UCLA.

Rey Mozer· Associate, aMoon Growth

Rey Mozer is an Associate at aMoon Growth, where she sources and evaluates late-stage investments in HealthTech and MedTech and works with management teams on growth. Before aMoon, she was a consultant at McKinsey & Company advising MedTech, digital health, and healthcare organizations, and earlier practiced as a pediatric radiologist at Boston Children's Hospital / Harvard Medical School and Tufts Medical Center. She holds an MD from Yale School of Medicine, an MBA from the Wharton School, and a BA in Biology from Cornell University, with residency and fellowship training at Brigham and Women's Hospital and Boston Children's Hospital.

Sharon Feldman· Investment Analyst

Sharon Feldman is an investment analyst at aMoon focused on evaluating and supporting healthcare companies. Before joining the firm, she founded and led the Jerusalem chapter of Nucleate Israel, building a life sciences community connecting researchers, entrepreneurs, clinicians, and investors, and worked on translating academic science into venture-backed opportunities. She previously served as Head Teaching Assistant in Biochemistry at The Hebrew University of Jerusalem and as an elected representative on the Junior Academic Staff Union Board.

Avital Adler· Analyst· Tel Aviv, Israelin

Avital Adler is a principal at Arkin Bio Ventures within Arkin Capital, where she leads early and late-stage investments. She previously spent four years at aMoon as a scientific and business diligence lead for biotech and diagnostics investments and helped establish aMoon Edge, the firm's public markets platform. Adler holds a PhD in Neural Computation from the Hebrew University, conducted postdoctoral research at NYU Medical Center, and has authored 21 peer-reviewed publications.

What they invest in

from 29 of 51 portfolio companies

Biotech ×19Healthtech ×17Digital Health ×11AI & Machine Learning ×6Medical Devices ×5Deep Tech ×4Mental Health ×3SaaS ×2

HQs:United States×16Switzerland×1Israel×1

Who they back

founder profiles across 11 portfolio companies

45%

solo founders

5 of 11 mapped founding teams

Founding team size:solo founder×52 founders×43 founders×2

Investments · 51 tracked

founders shown can be your intro path

By year:2026 · 2 2025 · 3 2024 · 1 2023 · 2 2022 · 1 2020 · 1 2019 · 111 dated

Adicet Bioadicetbio.comNASDAQ: ACETJul 2019SEC filingmedium confidence

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.

BiotechHealthtechMenlo Park, US

Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)

BoardJonathan Silverstein(Director)inCarl Gordon(Director)inFlorent Gros(Director)Erez Chimovits(Director)in

Board seatYair Schindel· per SEC Form D · $80M raise · filed Oct 2019

Co-investorsForesite Capital OrbiMed Pontifax Venture Capital Quan Capital Novartis Venture Fund

Seerseer.bio inNASDAQ: SEER

Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples.

BiotechDeep TechHardwareHealthtech

Omid Farokhzad(Chair and Chief Executive Officer)in

Co-investorsSoftBank Vision Fund Solasta Ventures Wing Maverick Ventures

Sera Prognosticsseraprognostics.com in 𝕏NASDAQ: SERA

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.

BiotechDigital HealthFemTechHealthtechSalt Lake City, US

Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)Gregory C. Critchfield(Executive Officer, Director)Andrew A. Sauter(Executive Officer)

BoardMansoor Mirza(Director)Ryan M. Trimble(Director)

Co-investorsExcelestar Ventures OUP (Osage University Partners)UpStart Ventures Vivo Capital Catalyst Health Ventures Domain Associates

Adcytherixadcytherix.com in✓ verified

Adcytherix is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) that use approved cancer drugs as payloads combined with optimized conjugation design to overcome resistance in precision oncology.

BiotechHealthtechMedical Devices

Jack Elands(Founder & CEO)inXavier Preville(Co-founder, VP & Head of Research & Preclinical Development)inJan H.M. Schellens(Chief Medical Officer)inThierry Menguy(VP & Head of CMC Operations)inJaime Arango(Chief Financial Officer)inPaul Jackson(Chief Operating Officer)in

Co-investorsRA Capital Bpifrance Andera Partners Angelini Ventures Kurma Partners Pontifax Venture Capital +1 more

Iantrekiantrekmed.com in✓ verified

Iantrek develops micro-interventional ophthalmic surgical technologies focused on enhancing total outflow through the uveoscleral pathway to treat glaucoma.

BiotechHealthtechMedical DevicesElkins Park, US

Tsontcho Ianchulev(Executive Officer, Director)Sean Ianchulev(Founder & Chairman of the Board (CMO))Michael Haydin(Executive Officer)

BoardJeffry K Weinhuff(Director)Farrell Tyson(Director)Stephen Bloch(Director)in

Co-investorsVisionary Ventures Canaan Partners Civilization Ventures Management, Llc FemHealth Ventures JSD Capital, LLC US Venture Partners

Scipher Medicinesciphermedicine.com in 𝕏✓ verified

Scipher Medicine is a precision immunology company that combines molecular data from autoimmune patients, protein interaction mapping, and AI to match patients with the most effective therapy for immunological diseases.

AI & Machine LearningBiotechDigital Health

Joseph Loscalzo(Founder | Physician-in-Chief, Brigham and Women's Hospital)Albert-László Barabási(Founder | Professor, Harvard and Northeastern University)

Co-investorsKhosla Ventures B3 Holding Cobalt Ventures Echo Health Ventures Hitachi Ventures Optum Ventures +1 more

Better Life Partnersbetterlifepartners.com in 𝕏Aug 2023

Better Life Partners provides same-day medication-assisted treatment for opioid and alcohol addiction, combining counseling, community support, and medication for people in recovery.

Digital HealthHealthtechMental HealthHanover, US

Adam Groff(Executive Officer, Director)Juliana Ekong(Executive Officer, Director)Myechia Minter-Jordan(Director)Steven Kelly(Executive Officer)

BoardJon Lim(Director)in

Board seatYair Schindel· per SEC Form D

Co-investorsF-Prime Capital .406 Ventures Maverick Ventures

DZZOM DelawareJul 2024SEC filingmedium confidence

BiotechBoston, US

Albert Laszlo Barabsi(Director)Marcell Veidner(Executive Officer, Director, Promoter)

BoardPeter Ruppert(Director)

Board seatTodd Sone· per SEC Form D · $5.8M raise · filed Jul 2024

Hometown Medical HoldingsSep 2025SEC filingmedium confidence

New York, US

KRISTIN MYERS PENG(CHIEF EXECUTIVE OFFICER AND MANAGER)BURKE WISE(VICE PRESIDENT, TREASURER, SECRETARY AND MANAGER)

BoardTREVOR PRICE(MANAGER)SEBASTIAN CALIRI(MANAGER)

Board seatYair Schindel· per SEC Form D · $61.6M raise · filed Apr 2026

Satellite BiosciencesMar 2022

Cambridge, US

Board seatYair Schindel· per SEC Form D

Viracta TherapeuticsNov 2020SEC filingmedium confidence

BiotechSan Diego, US

James Woody(Director)David Slack(Executive Officer)

BoardIvor Royston(Executive Officer, Director)Patrick Soon-Shiong(Director)Richard Ghalie(Director)

Board seatGur Roshwalb· per SEC Form D · $40M raise · filed Dec 2020

Adicet

Air Doctor

Akoyabioakoyabio.com in 𝕏acquired by Quanterix

BiotechHealthtechMedical DevicesBillerica, US

Brian McKelligon(Executive Officer)Garry Nolan(Director)Matthew Winkler(Director)

BoardRob Hart(Executive Officer)inRobert Shepler(Director)inThomas Raffin(Director)in

Co-investorsTelegraph Hill Partners

AltruBioaltrubio.com

AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.

BiotechHealthtech

Co-investorsDelos Capital RA Capital

Ayalapharmaayalapharma.com

Ayala Pharma is associated with pharmaceutical drug candidates including AL102, AL101, and BST-236; the page states that AL102 and AL101 were acquired by Immunome, Inc. in Q1 2024.

Biotech

Co-investorsIsrael Biotech Fund

Biolojic Designbiolojic.com in 𝕏

Biolojic uses machine learning to design programmable human antibodies, including epitope-specific binders and multi-specific "multibodies," that act as functional switches targeting validated biological pathways.

AI & Machine LearningBiotechDeep Tech

Co-investorsOurCrowd Western Technology Investment

Biosplice Therapeutics

BiotechSan Francisco, US

Karen McGinnis(Director)Susannah Gray(Director)Cevdet Samikoglu(Director)Joy Ghosh(Director)Arman Oruc(Secretary)Osman Kibar(President and Director)

Breeoot Clinic

CartiHeal

Developer of implant technology for cartilage and osteochondral defects; sold to Smith and Nephew in 2023.

Co-investorsAccelmed Partners Peregrine Ventures

CAVOS

Character Biocharacterbio.com inMar 2025

Character Bio is a precision medicine company that integrates genomics, longitudinal clinical data, imaging, and AI-based biomarker analysis to identify genetic drivers of progressive polygenic eye diseases such as age-related macular degeneration and glaucoma.

AI & Machine LearningBiotechDigital HealthJersey City, US

Cheng Zhang(Executive Officer, Director)

BoardVivek Garipalli(Director)Nick Olsen(Director)Peter DiLaura(Director)

Co-investorsCantos Ventures Catalio Capital Management, LP Duke Capital Partners Lifeforce Capital Sanofi Ventures Catalio Capital Management +3 more

Coltac Therapeutics

Connie Healthconniehealth.com inJun 2026 · $40M

Connie Health helps older Americans choose and navigate Medicare plans by combining technology with local licensed agents, providing unbiased plan recommendations and an ongoing local care team at no cost to the user.

Digital HealthHealthtechInsurTech

Oded Eran(Co-founder)inDavid Luna(Co-founder)inMichael Scopa(Co-founder)in

Co-investorsAbstract Ventures Arkitekt Ventures at.inc/HealthQuest Capital J-Ventures JSL Health Capital +2 more

Eleos Healtheleos.health inNov 2023 · $40M

Eleos develops AI-powered software that helps behavioral health clinicians deliver more effective care through data measurement and personalization.

AI & Machine LearningDigital HealthHealthtechMental HealthCambridge, US

Alon Joffe(Chief Executive Officer)inDror Zaide(Chief Revenue Officer)inAlon Rabinovich(Chief Technology Officer)inDenny Morrison(Chief Clinical Officer)inRaz Karmi(Chief Information Security Officer)inNoam Cohen(VP of R&D)in

Co-investorsArkin Capital F-Prime Capital Greenfield Partners Lool Ventures Maccabee Ventures Menlo Ventures +2 more

GK8gk8.io in 𝕏acquired by Celsius Network

GK8 developed self-managed digital asset custody technology for institutions, including a patented air-gapped cold vault and MPC-based wallet infrastructure.

Crypto & Web3CybersecurityFintech

Co-investorsCV VC IN Venture iAngels

GraphiteRx

Hopscotch Primary Care

IBEX

KAHR

Linlin.health inDec 2025 · $11M

Lin Health provides virtual, evidence-based behavioral healthcare for people with chronic pain, using the Collaborative Care model and a technology platform to address the underlying causes of pain rather than only symptoms.

Digital HealthHealthtechMental HealthWellness & Fitness

Yehuda Kogan(Founder)in

Co-investorsSaban Ventures Shoni Health Ventures Viola Ventures Osage Venture Partners Proofpoint Capital

Lin Health

Lutris Pharmalutris-pharma.com in

Lutris Pharma is a clinical-stage biopharmaceutical company developing LUT014, a topical B-RAF inhibitor gel intended to reduce acneiform rash and other skin side effects caused by cancer therapies such as EGFR and RAS inhibitors.

BiotechHealthtech

Co-investorsPeregrine Ventures Pontifax Venture Capital

Lyfegenlyfegen.com in 𝕏

Lyfegen provides a software platform for managing value-based and outcome-based healthcare contracts and drug pricing agreements between pharmaceutical companies, health insurers (payers), and providers.

Digital HealthHealthtechSaaSBasel, CH

Girisha Fernando(Founder)inMichel Mohler(Founder)Nico Julian Mros(Founder)

Co-investorsTX Ventures

Mdclonemdclone.com in 𝕏

MDClone offers the ADAMS Platform, a self-service healthcare data exploration environment that lets healthcare institutions access and analyze health data for research, collaboration, and operational improvements.

AI & Machine LearningData & InfrastructureDigital Health

Co-investorsDeclaration Partners Lightspeed Venture Partners OrbiMed Viola Ventures Warburg Pincus

MetaSight

MiNA Therapeutics

Biotech company that secured funding with Bootstrap Europe's support during a difficult environment for growing biotech businesses.

Co-investorsBootstrap Europe

MOBILion Systems, Inc.

NanoGhostnano-ghost.com

NanoGhost develops a drug targeting platform called Nano-Ghosts (NGs), nanovesicles made from the cell membrane of mesenchymal stem cells that target cancer and inflammation sites and can carry various therapeutic loads.

BiotechDeep TechHealthtech

Marcelle Machluf(Professor (technology inventor))

Nectin Therapeutics

Omada

PacegenixMar 2026

BiotechCambridge, US

Jay Glenn Wohlgemuth(Executive Officer, Director)Frank Grazzini, II(Executive Officer)

BoardFredric Neville Eshelman(Director)Raymond Tabibiazar(Director)

Positive Development

PrognomIQprognomiq.com in 𝕏

HealthtechSan Mateo, US

Philip Ma, Ph.D.(Executive Officer, Director)Brian Koh, M.D.(Executive Officer)David Siewers(Executive Officer)Omid Farokhzad, M.D.(Director)

BoardTomer Berkovitz, Ph.D.(Director)Rajesh Garg(Director)

Co-investorsCatalio Capital Management, LP Wing Maverick Ventures

Seerhelloseer.com in 𝕏

Seer provides a platform for sales associates in luxury retail to create and share customized lookbooks and style recommendations with clients.

Enterprise SoftwareRetail TechSaaSSan Francisco, US

Christina Czap(Founder)inFelipe Saint-Jean(Founder)in

Co-investorsOpen Opportunity Fund Y Combinator

Sophia Geneticssophiagenetics.com in 𝕏

SOPHiA GENETICS provides an AI-driven, cloud-based platform (SOPHiA DDM) that analyzes genomic data to help clinicians produce actionable insights for patients with cancer and rare disorders.

AI & Machine LearningBiotechDigital Health

Co-investors360 Capital Balderton Capital Compound Hitachi Ventures ACE & Company

Theranica

Combines neuro-modulation with wireless communications and smartphone apps for effective therapy treatments.

Co-investorsLightspeed Venture Partners LionBird New Rhein Healthcare Investors, LLC

Theranica Bio-Electronicstheranica.com in 𝕏

Theranica develops prescription digital therapeutics for pain management, including Nerivio, a wearable device that uses remote electrical neuromodulation of upper arm nerves to trigger the body's Conditioned Pain Modulation mechanism.

Digital HealthHealthtechMedical Devices

Alon Ironi(Founder)in

Co-investorsLionBird Vivo Capital Lightspeed Venture Partners

Ultima Genomicsultimagenomics.com in 𝕏

Ultima Genomics develops genomic sequencing technology to scale omics information for advances in biology and human health improvements.

BiotechDeep TechHealthtechMedical Devices

Gilad Almogy(Founder)in

Co-investorsAndreessen Horowitz Khosla Ventures Playground Global Founders Fund General Atlantic

Viracta

Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).

Co-investorsBay City Capital Latterell Venture Partners

Zebra Medical Vision

FDA approved AI-powered medical imaging software to enhance image quality

Co-investorsFoothill Ventures Khosla Ventures

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 5

IPOs and acquisitions across the tracked portfolio

Adicet BioNASDAQ: ACETSeerNASDAQ: SEERSera PrognosticsNASDAQ: SERAAkoyabioacq. by QuanterixGK8acq. by Celsius Network

Portfolio news

latest coverage across their companies

Seer president & CFO David Horn sells $14,809 in company stock By Investing.com

Seer · investing.com · Aug 20, 2026

Sera Prognostics Still Needs Revenue Proof to Match Its Clinical Momentum - Alphastreet

Sera Prognostics · news.alphastreet.com · Aug 20, 2026

Seer (SEER) Q2 2026 Earnings Call Transcript - AOL

PrognomIQ · aol.com · Aug 18, 2026

RA Capital reports 9.99% stake in Adicet Bio | ACET SEC Filing - Form SCHEDULE 13G/A

Adicet Bio · stocktitan.net · Aug 14, 2026

BTIG raises Sophia Genetics stock price target on CDx deals By Investing.com

Sophia Genetics · investing.com · Aug 5, 2026

Ultima Genomics - Wikipedia

Ultima Genomics · en.wikipedia.org · Jul 25, 2026

Connie Health raises $40 million | Venture5

Connie Health · venture5.com · Jul 8, 2026

Seer Files Investor Presentation Highlighting Strong Momentum, Commercial Opportunity and Significant Long-Term Value Creation Potential | SEER Stock News

Seer · stocktitan.net · Jul 6, 2026

Frequently asked questions

How many investments has aMoon made?: aMoon has 44 tracked investments, 1 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
What stage does aMoon invest at?: aMoon invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What sectors does aMoon focus on?: aMoon focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is aMoon located?: aMoon is headquartered in Ra'anana, IL.
Who does aMoon co-invest with?: aMoon most often shares deals with F-Prime Capital, Khosla Ventures, Lightspeed Venture Partners, among 76 tracked co-investors.

Media · Podcasts & interviews

from their channel

aMoon Portfolio Spotlight: MiNA Therapeutics

aMoon Fund

aMoon Portfolio Spotlight: Satellite Bio

aMoon Fund

aMoon Portfolio Spotlight: SOPHiA GENETICS

aMoon Fund

aMoon Portfolio Spotlight: MDClone

aMoon Fund

Meet the aMoon Advisors

aMoon Fund

aMoon Velocity

aMoon Fund

Images

Co-investors · 17

Khosla Ventures

Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.

Both backed · 4

Connie Health Scipher Medicine Ultima GenomicsZebra Medical Vision

$5K – $50M

Lightspeed Venture Partners

Lightspeed is a global venture capital firm that has spent over two decades backing innovative companies as an early and first investor.

Both backed · 3

Mdclone Theranica Bio-ElectronicsTheranica

$1.7M – $87M

F-Prime Capital

F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.

Both backed · 2

Better Life Partners Eleos Health

$3M – $10M

Viola Ventures

Viola is an Israeli technology investment group managing over $7 billion in assets, operating multiple independent investment arms spanning venture capital, growth equity, credit, and fintech.

Both backed · 2

Lin Mdclone

$1.4M – $32M

Vivo Capital

Vivo Capital is a global healthcare-focused investment firm operating a multi-strategy platform spanning venture capital, private equity, and public equity. It aims to expand healthcare access and drive innovation through its 'Ecosystem Strategy.'

Both backed · 2

Sera Prognostics Theranica Bio-Electronics

$10M – $50M

US Venture Partners

US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.

Both backed · 1

Iantrek

$500K – $10M

.406 Ventures

.406 Ventures is an early-stage venture capital firm that partners with founders building companies in healthcare, data and AI, and cybersecurity.

Both backed · 1

Better Life Partners

$1M – $4M

Echo Health Ventures

Echo Health Ventures is a strategic venture capital and growth equity investor that partners with health care companies to help build and scale their innovations nationally.

Both backed · 1

Scipher Medicine

Alumni Ventures

Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.

$100K – $10M

B Capital Group

B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.

$10M – $50M

8VC

8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.

$100K – $50M

Polaris Partners

Polaris Partners is a venture capital firm that partners with biotech and healthcare entrepreneurs to build transformational companies.

$500K – $5M

▶5 more co-investors

Highbury Holdings S32 Northpond Ventures 10D Maverick Capital

Firms observed investing alongside aMoon, from public investor directories. Shared companies are the overlap with aMoon's recorded portfolio.

Similar investors

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

$250K – $50M

Khosla Ventures

$5K – $50M

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M

EQT Life Sciences

EQT Life Sciences, formerly LSP, is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally. It is part of EQT Group.

$11M – $66M

Ally Bridge Group

Ally Bridge Group is a global healthcare investment manager focused on high-impact life sciences innovation across private and public markets.

Featured in lists

Seed Investors & VC Firms Series A Investors & VC Firms Growth Investors & VC Firms Series B Investors & VC Firms Investors & VC Firms in Global Healthtech Investors & VC Firms Late Stage Investors & VC Firms Series C Investors & VC Firms Seed Investors & VC Firms in Global Healthtech Seed Investors & VC Firms Healthtech Series A Investors & VC Firms Series A Investors & VC Firms in Global